Neurocrine(DE:NB3)
€154.85+4.40 (+2.92%)
DE:NB3
Neurocrine stock forecast
€154.85
At close:+4.40 (+2.92%)
Neurocrine (NB3) Stock Forecast & Price Target
1 Followers
NB3 Analyst Ratings
Strong Buy
18Buy3Hold0Sell
Based on 21 analysts giving stock ratings to Neurocrine in the past 3 months
NB3 Stock 12 Month Forecast
Average Price Target
€185.12▲(19.55% Upside)Based on 21 Wall Street analysts offering 12 month price targets for Neurocrine in the last 3 months. The average price target is EUR 185.12 with a high forecast of EUR 226.89 and a low forecast of EUR 134.52. The average price target represents a 19.55% change from the last price of EUR 154.85.
Past 12 Months12 Month ForecastJan2026Oct2026
High€226.89
Average€185.12
Low€134.52
Highest Price TargetHighest€226.89Average Price Target€185.12Lowest Price TargetLowest€134.52
Detailed List of Analyst Forecasts​
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Sean Laaman | Morgan Stanley | €164.12→€165.91 | hold | 7.14%Upside | Reiterated | 11/03/26 | ||
| Mohit Bansal | Wells Fargo | €179.36 | buy | 15.83%Upside | Assigned | 11/03/26 | ||
| David Amsellem | Piper Sandler | €188.33→€192.81 | buy | 24.52%Upside | Reiterated | 11/03/26 | ||
| Sumant Kulkarni | Canaccord Genuity | €188.33→€197.30 | buy | 27.41%Upside | Reiterated | 11/03/26 | ||
| Laura Chico | Wedbush | €166.81 | buy | 7.72%Upside | Reiterated | 11/03/26 | ||
| Jay Olson | Oppenheimer | €206.26 | buy | 33.20%Upside | Reiterated | 11/03/26 | ||
| David Hoang | Deutsche Bank | €147.97→€156.94 | hold | 1.35%Upside | Reiterated | 11/03/26 | ||
| Tazeen Ahmad | Bank of America Securities | ― | buy | ― | Reiterated | 11/03/26 | ||
| Delma Caiati | Guggenheim | €185.64→€200.88 | buy | 29.73%Upside | Reiterated | 11/03/26 | ||
| Jeffrey Walch | Bernstein | €195.50 | buy | 26.25%Upside | Reiterated | 11/03/26 | ||
| Phil Nadeau | TD Cowen | €197.30 | buy | 27.41%Upside | Reiterated | 11/03/26 | ||
| Anupam Rama | J.P. Morgan | ― | buy | ― | Reiterated | 11/02/26 | ||
| Joshua Schimmer | Cantor Fitzgerald | €192.81 | buy | 24.52%Upside | Reiterated | 11/02/26 | ||
| Brian Abrahams | RBC Capital | €167.70→€170.39 | buy | 10.04%Upside | Reiterated | 11/02/26 | ||
| Evan Seigerman | BMO Capital | €134.52 | hold | -13.13%Downside | Reiterated | 11/02/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Sean LaamanMorgan Stanley | HoldReiterated€164.12→€165.91 | 11/03/26 | 7.14%Upside | ||
| Mohit BansalWells Fargo | BuyAssigned€179.36 | 11/03/26 | 15.83%Upside | ||
| David AmsellemPiper Sandler | BuyReiterated€188.33→€192.81 | 11/03/26 | 24.52%Upside | ||
| Sumant KulkarniCanaccord Genuity | BuyReiterated€188.33→€197.30 | 11/03/26 | 27.41%Upside | ||
| Laura ChicoWedbush | BuyReiterated€166.81 | 11/03/26 | 7.72%Upside | ||
| Jay OlsonOppenheimer | BuyReiterated€206.26 | 11/03/26 | 33.20%Upside | ||
| David HoangDeutsche Bank | HoldReiterated€147.97→€156.94 | 11/03/26 | 1.35%Upside | ||
| Tazeen AhmadBank of America Securities | BuyReiterated | 11/03/26 | ― | ||
| Delma CaiatiGuggenheim | BuyReiterated€185.64→€200.88 | 11/03/26 | 29.73%Upside | ||
| Jeffrey WalchBernstein | BuyReiterated€195.50 | 11/03/26 | 26.25%Upside | ||
| Phil NadeauTD Cowen | BuyReiterated€197.30 | 11/03/26 | 27.41%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated | 11/02/26 | ― | ||
| Joshua SchimmerCantor Fitzgerald | BuyReiterated€192.81 | 11/02/26 | 24.52%Upside | ||
| Brian AbrahamsRBC Capital | BuyReiterated€167.70→€170.39 | 11/02/26 | 10.04%Upside | ||
| Evan SeigermanBMO Capital | HoldReiterated€134.52 | 11/02/26 | -13.13%Downside |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Neurocrine
3 Months
Success Rate17/27 ratings generated profit
63%
Average Return
+3.23%
Copying Jay Olson's trades and holding each position for 3 Months would result in 62.96% of your transactions generating a profit, with an average return of +3.23% per trade.
1 Year
Success Rate15/19 ratings generated profit
79%
Average Return
+11.52%
Copying Tazeen Ahmad's trades and holding each position for 1 Year would result in 78.95% of your transactions generating a profit, with an average return of +11.52% per trade.
2 Years
Success Rate17/19 ratings generated profit
89%
Average Return
+20.99%
Copying Tazeen Ahmad's trades and holding each position for 2 Years would result in 89.47% of your transactions generating a profit, with an average return of +20.99% per trade.
NB3 Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 1 | 4 | 6 | 6 |
| Buy | 44 | 36 | 35 | 17 | 22 |
| Hold | 8 | 9 | 10 | 7 | 5 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 56 | 46 | 49 | 30 | 33 |
In the current month, NB3 has received 28 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. NB3 average Analyst price target in the past 3 months is 185.12.
NB3 Financial Forecast
High€2.84
Consensus€1.85
Low€1.23
NB3 Earnings Forecast
Next quarter’s earnings estimate for NB3 is EUR 1.85 with a range of EUR 1.23 to EUR 2.84. The previous quarter’s EPS was EUR 1.75. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High€1.15B
Consensus€978M
Low€945M
NB3 Sales Forecast
Next quarter’s sales forecast for NB3 is EUR 978.31M with a range of EUR 944.59M to EUR 1.15B. The previous quarter’s sales results were EUR 1.01B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
NB3 Stock Forecast FAQ
What is DE:NB3’s average 12-month price target, according to analysts?
Based on analyst ratings, Neurocrine’s 12-month average price target is €185.12.
What is DE:NB3’s upside potential, based on the analysts’ average price target?
Neurocrine has 19.55% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Neurocrine a Buy, Sell or Hold?
Neurocrine has a consensus rating of Strong Buy, which is based on 18 buy ratings, 3 hold ratings and 0 sell ratings.
What is Neurocrine’s share price target?
The average share price target for Neurocrine is €185.12. This is based on 21 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €226.89, and the lowest forecast is €134.52. The average share price target represents a 19.55% increase from the current price of €154.85.
What do analysts say about Neurocrine?
Neurocrine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Street analysts.
How can I buy shares of Neurocrine?
To buy shares of DE:NB3, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
